InvestSMART

Biotech awaits results

Drug maker Pharmaxis is sweating on the results of a clinical trial of cystic fibrosis drug Bronchitol.
By · 23 Apr 2013
By ·
23 Apr 2013
comments Comments
Upsell Banner
Drug maker Pharmaxis is sweating on the results of a clinical trial of cystic fibrosis drug Bronchitol. The biotech placed its shares in a trading halt on Monday before the results of the phase III trial, expected this week. The move was just two months after the drug was rejected by the main US regulatory body, which sent Pharmaxis shares into a tailspin.
Share this article and show your support
Free Membership
Free Membership
InvestSMART
InvestSMART
Keep on reading more articles from InvestSMART. See more articles
Join the conversation
Join the conversation...
There are comments posted so far. Join the conversation, please login or Sign up.